Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
An update from Theranexus SA ( (FR:ALTHX) ) is now available.
Theranexus has released its semi-annual report for its liquidity contract with Portzamparc, revealing an increase in the number of shares and a decrease in euros compared to previous figures. This update reflects on the company’s financial positioning and its operational strategy for managing liquidity, which might affect stakeholder perspectives.
More about Theranexus SA
Theranexus is an innovative biopharmaceutical company originating from the CEA, focusing on the treatment of rare neurological diseases. It has a unique platform for drug candidate identification and characterization and is developing its first drug candidate for Batten disease. Theranexus is listed on the Euronext Growth market in Paris.
YTD Price Performance: -7.04%
Average Trading Volume: 4,497
Technical Sentiment Consensus Rating: Hold
Current Market Cap: €4.1M
For detailed information about ALTHX stock, go to TipRanks’ Stock Analysis page.
